MODULAR NEXT GENERATION

IMMUNOTHERAPY

NEW & INNOVATIVE THERAPIES

CYTEA|BIO is developing therapeutic products by combining novel targeting ligands with unmodified allogeneic effector cells via natural receptors.

OUR PATENTED PIN™ PLATFORM ENABLES PRACTICALLY LIMITLESS COMBINATIONS OF EFFECTOR MECHANISMS AND TARGETING LIGANDS, BUILDING NEW AND INNOVATIVE THERAPIES WITHOUT NEED FOR DRUG DISCOVERY, WITH UNRIVALLED EFFICACY, SAFETY AND MANUFACTURING / REGULATORY ECONOMICS.

4+

(POTENTIAL PRODUCT CANDIDATES)

(THE COMPANY)

OUR COMPANY

CYTEA|BIO IS A PRE-CLINICAL STAGE BIOTECHNOLOGY COMPANY BASED IN MONTPELLIER, FRANCE DEDICATED TO THE DEVELOPMENT OF INNOVATIVE IMMUNOTHERAPY PRODUCTS

6+

(YEARS OF ACADEMIC RESEARCH BEHIND THE PLATFORM)

CYTEA|BIO HAS DEVELOPED AND PATENTED A VERSATILE AND MODULAR IMMUNOTHERAPY PLATFORM (PIN™ PLATFORM). THE PLATFORM IS UNIQUE IN ITS APPROACH TO UTILIZE UNMODIFIED (THEREFORE POTENT AND SAFE) IMMUNE EFFECTOR CELLS TARGETED TO PATHOLOGICAL CELLS THROUGH RECOGNITION LIGANDS OCCUPYING NATURAL RECEPTORS ON THE THERAPEUTIC CELL SURFACE. THE PIN™ PLATFORM ENABLES VIRTUALLY ANY HUMANIZED MONOCLONAL ANTIBODY TO BE EMPLOYED AS A TARGETING LIGAND AS WELL AS A WIDE RANGE OF FC – BASED CONSTRUCTS. 

SIMPLE Fc ENGINEERING ENABLES LIGANDS TO BE FIRMLY BOUND TO A NORMAL EFFECTOR CELL DURING MANUFACTURE.
THE PIN™ PLATFORM SUPPORTS THERAPEUTIC USES OF BOTH ALLOGENEIC AND AUTOLOGOUS UNMODIFIED EFFECTOR CELLS.  WHEN COMBINED WITH APPROPRIATE SINGLE OR MULTIPLE LIGAND(S), AN ALMOST UNLIMITED NUMBER OF COMBINATIONS ARE POSSIBLE, PROVIDING SENSING, TARGETING, ACTIVATION AND POTENT THERAPEUTIC EFFECT WITH LOW DEVELOPMENT RISK AND EXCEPTIONALLY POSITIVE ECONOMICS IN MANUFACTURING AND REGULATORY SUBMISSIONS.

(CONCEPT)

OUR TECHNOLOGY

PLATFORM

NOVEL TARGETING LIGANDS AND UNMODIFIED EFFECTOR CELLS.

Unmodified human effector cells armed with engineered antibodies or engineered Fc ligands, selected to target disease markers

PIPELINE

TREATING VARIOUS PATHOLOGIES

ROBUST PRE-CLINICAL POC ACHIEVED WITH ALLOGENEIC NATURAL KILLER (NK) CELLS ARMED AGAINST SEVERAL TARGETS. LEAD TUMOR DEVELOPMENT PROGRAM FOR PRIMARY AND RECURRENT GLIOBLASTOMA MULTIFORME (GBM), TARGETING EGFR AND/OR HER2. SECONDARY DEVELOPMENT FOR OTHER TUMORS SHARING SAME TARGET(S).

(SUPPORT)

OUR PARTNERS